Drugs / XYF19 CAR-T cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04037566 | Aug 2019 → Aug 2021 | B-cell non-Hodgkin lymphoma, acute lymphoblastic leukemia | Xijing Hospital | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XYF19 CAR-T cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04037566 ↗ |
| Modality | Cell therapy | “CD19-specific CAR-T cells” NCT04037566 ↗ |
| Route | Intravenous | “administered by IV injection” NCT04037566 ↗ |
| Target | CD19 | “Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1” NCT04037566 ↗ |
| Target | HPK1 | “Autologous T cells engineered to specify CD19 transduced with a lentiviral vector and electroporated with CRISPR guide RNA to disrupt expression of endogenous HPK1” NCT04037566 ↗ |